GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NxStage Medical Inc (NAS:NXTM) » Definitions » Equity-to-Asset

NxStage Medical (NxStage Medical) Equity-to-Asset : 0.60 (As of Sep. 2018)


View and export this data going back to 2005. Start your Free Trial

What is NxStage Medical Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NxStage Medical's Total Stockholders Equity for the quarter that ended in Sep. 2018 was $225.2 Mil. NxStage Medical's Total Assets for the quarter that ended in Sep. 2018 was $377.4 Mil. Therefore, NxStage Medical's Equity to Asset Ratio for the quarter that ended in Sep. 2018 was 0.60.

The historical rank and industry rank for NxStage Medical's Equity-to-Asset or its related term are showing as below:

NXTM's Equity-to-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.65
* Ranked among companies with meaningful Equity-to-Asset only.

NxStage Medical Equity-to-Asset Historical Data

The historical data trend for NxStage Medical's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NxStage Medical Equity-to-Asset Chart

NxStage Medical Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.62 0.63 0.64 0.66

NxStage Medical Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.66 0.66 0.66 0.60

Competitive Comparison of NxStage Medical's Equity-to-Asset

For the Medical Instruments & Supplies subindustry, NxStage Medical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NxStage Medical's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NxStage Medical's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where NxStage Medical's Equity-to-Asset falls into.



NxStage Medical Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

NxStage Medical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Equity to Asset (A: Dec. 2017 )=Total Stockholders Equity/Total Assets
=213.158/325.629
=0.65

NxStage Medical's Equity to Asset Ratio for the quarter that ended in Sep. 2018 is calculated as

Equity to Asset (Q: Sep. 2018 )=Total Stockholders Equity/Total Assets
=225.192/377.449
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NxStage Medical  (NAS:NXTM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


NxStage Medical Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of NxStage Medical's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NxStage Medical (NxStage Medical) Business Description

Traded in Other Exchanges
N/A
Address
NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.
Executives
Earl R Lewis director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Craig W Moore director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Jeffrey H Burbank director, officer: Chief Executive Officer NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
James J Peters director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Kevin Hershberger officer: Chief Accounting Officer 350 MERRIMACK STREET, LAWRENCE MA 01843
Philippe O. Chambon director C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NxStage Medical (NxStage Medical) Headlines